文献速递淋巴瘤造血干细胞移植与细胞治疗

复发或难治性PTCL-NOS或AITL的自体或异基因造血细胞移植

Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.
PubMed 文献 · Leukemia · 2022-03-28

该回顾性研究纳入760例接受首次造血细胞移植的成人复发或难治性PTCL-NOS或AITL患者,其中318例为首次缓解后复发、442例为原发治疗难治。4年总生存率在自体移植与异基因移植间相近,但多因素分析显示异基因移植在难治患者中无进展生存显著更优(HR 0.64)。

要点

  • 复发患者自体与异基因移植4年OS均为50%,难治患者分别为52%与49%。
  • 多因素分析中异基因移植在复发患者PFS趋于更优(HR 0.74,95%CI 0.53-1.03)。
  • 难治患者异基因移植PFS显著优于自体移植(HR 0.64,95%CI 0.46-0.88)。

核心结论

  • 异基因移植对复发或难治性PTCL-NOS或AITL的优势因移植时疾病状态而异。

研究设计与样本

  • 回顾性评估760例接受首次造血细胞移植的成人复发或难治性PTCL-NOS或AITL患者,其中318例为首次缓解后复发,442例为原发治疗难治。

主要发现

  • 自体移植与异基因移植的4年总生存率在复发患者中均为50%,在难治患者中分别为52%与49%。
  • 多因素分析中,与自体移植相比,异基因移植在复发患者中PFS趋于更优(HR 0.74;95%CI 0.53-1.03)。
  • 多因素分析中,与自体移植相比,异基因移植在难治患者中PFS显著更优(HR 0.64;95%CI 0.46-0.88)。
  • 倾向评分匹配的亚组分析显示,异基因移植在复发敏感和难治未缓解患者中与更优OS相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fit patients with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) in relapsed or refractory (R/R) disease status often receive salvage chemotherapy followed by autologous hematopoietic stem cell transplantation (autoHCT) or allogeneic HCT (alloHCT). However, there is no consensus on the type of HCT that should be applied for such patients. Herein, we retrospectively evaluated the survival outcome of 760 adult R/R PTCL-NOS or AITL patients who underwent the first HCT. Among them, 318 relapsed after first remission (REL) and 442 were refractory to the primary therapy (PIF). The 4-year overall survival (OS) of autoHCT and alloHCT was 50 and 50% for REL patients, and 52 and 49% for PIF patients, respectively. In the multivariable analysis, alloHCT tended to be associated with better progression-free survival (PFS) in REL (hazard ratio [HR] 0.74; 95% confidence interval [CI]: 0.53-1.03), and significantly better PFS in PIF (HR 0.64; 95% CI: 0.46-0.88) compared with autoHCT. The subgroup analysis with propensity-score matching showed that alloHCT was associated with better OS for REL-sensitive and PIF-nonremission disease. This study suggested that the advantage of alloHCT for R/R PTCL-NOS or AITL is different, depending on the disease status at HCT.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kameda K, Kako S, Kim SW, et al. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia. 2022. PMID: 35347237. doi:10.1038/s41375-022-01545-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。